Fig. 3

Induction of IL-33 by LPS, SAA1, IL-1β and IL-33 in human amnion fibroblasts. (A-C) Concentration-dependent effects of LPS (1, 10 and 50 ng/mL; 24 h; A), IL-1β (0.1, 1 and 10 ng/mL; 24 h; B) and SAA1 (1, 10 and 50 ng/mL; 24 h; C) on IL33 mRNA and protein abundance in amnion fibroblasts. n = 3–4. (D-F) Effects of LPS (50 ng/mL; 24 h; D), IL-1β (10 ng/mL; 24 h; E) and SAA1 (50 ng/mL; 24 h; F) on IL-33 secretion. n = 3–4. (G) Concentration-dependent effect of IL-33 (50, 100 and 200 ng/mL; 8 h) on IL33 mRNA and protein abundance in amnion fibroblasts. n = 3–4. (H-K) Blockade of LPS (10 ng/mL; 24 h)-, IL-1β (10 ng/mL; 24 h)-, SAA1 (50 ng/mL; 24 h)- and IL-33 (100 ng/mL; 8 h)-induced increases in IL-33 protein abundance by NF-κB inhibitor JSH-23 (JSH; 10 µM). n = 3. Bottom panels are the representative immunoblots and top panels are the average data. Data are mean ± SEM. Statistical analysis was performed with one-way ANOVA test followed by the Newman-Keuls multiple comparison test (A-C, G-K) or paired Student’s t-test (D-F). *p < 0.05, **p < 0.01, ***p < 0.001 vs. 0 ng/mL; #p < 0.05, ##p < 0.01 vs. LPS-, IL-1β-, SAA1- or IL-33-treated groups